Gocovri Approved by FDA as 1st Treatment for Levodopa-induced Dyskinesia in Parkinson’s Patients

Gocovri Approved by FDA as 1st Treatment for Levodopa-induced Dyskinesia in Parkinson’s Patients
The first treatment for levodopa-induced dyskinesia — the involuntary and jerky movements that afflict most Parkinson’s disease patients on this common therapy — was approved Thursday, Aug. 24, by the U.S. Food and Drug Administration. The therapy, Gocovri (amantadine) by Adamas Pharmaceuticals, is an long-acting and extended-release capsule, indicated for those receiving levodopa-based therapy, with or without other dopaminergic medications. These are ... read more
Source: Parkinson’s News TodayPublished on 2017-08-25By Patricia Inacio, PhD